Table 1.
Characteristics of HIV-positive individuals who did and did not interrupt treatment in the 12 month period before or after LISA interview date (N=768)
| Characteristic | N | No treatment Interruption n (%) n = 651 |
Treatment Interruption n (%) n = 117 |
p – value |
|---|---|---|---|---|
| Gender | 768 | |||
| Male | 516 (79.2) | 68 (58.1) | <0.001 | |
| Female | 135 (20.7) | 49 (41.9) | ||
| Median age (IQR)* | 768 | 46 (41–52) | 42 (37–41) | 0.001 |
| History of IDU† | 766 | |||
| yes | 358 (55.1) | 90 (77.6) | <0.001 | |
| no | 292 (44.9) | 26 (22.4) | ||
| Current illicit drug use | 766 | |||
| yes | 325 (50.0) | 76 (65.5) | 0.002 | |
| no | 325 (50.0) | 40 (34.5) | ||
| Aboriginal | 768 | |||
| yes | 165 (25.4) | 46 (39.3) | 0.002 | |
| no | 486 (74.7) | 71 (60.7) | ||
| Completed High School | 767 | |||
| yes | 418 (64.3) | 58 (49.6) | 0.002 | |
| no | 232 (35.7) | 59 (50.4) | ||
| Earn ≥$15,000 | 762 | |||
| yes | 288 (44.6) | 30 (25.9) | <0.001 | |
| no | 358 (55.4) | 86 (74.1) | ||
| Ever Incarcerated | 767 | |||
| yes | 315 (48.5) | 76 (65.0) | 0.001 | |
| no | 335 (51.4) | 41 (35.0) | ||
| Currently Employed | 768 | |||
| yes | 177 (27.2) | 15 (12.8) | 0.001 | |
| no | 474 (72.8) | 102 (87.2) | ||
| Unstable Housing** | 767 | |||
| yes | 182 (28.0) | 54 (46.1) | <0.001 | |
| no | 468 (72.0) | 63 (53.9) | ||
| Who do you live with? | 766 | |||
| Live alone | 391 (60.1) | 57 (49.1) | <0.001 | |
| With ≥ 1 person | 250 (38.5) | 51 (44.0) | ||
| Homeless | 9 (1.4) | 8 (6.9) | ||
| Food insecure | 755 | 0.012 | ||
| Yes | 404 (62.2) | 87 (74.4) | ||
| No | 245 (37.8) | 30 (25.6) | ||
| Adherence ≥95%‡ | 761 | |||
| yes | 384 (59.6) | 38 (32.5) | <0.001 | |
| no | 260 (40.4) | 79 (67.5) | ||
| Ever depressed | 767 | 0.198 | ||
| Yes | 297 (45.7) | 61 (52.1) | ||
| No | 353 (54.3) | 56 (47.9) | ||
| Median CD4 cell count at treatment initiation* | 763 | 210 (120–330) | 215 (120–330) | 0.294 |
| AIDS at Baseline | 768 | |||
| yes | 94 (14.4) | 17 (14.5) | 0.980 | |
| no | 557 (85.6) | 100 (85.5) | ||
| Overall Health | 768 | |||
| Exc., very good, good | 453 (69.6) | 61 (52.1) | <0.001 | |
| vs. poor, fair | 198 (30.4) | 56 (47.9) | ||
| NRTI combo in cART regimen at interview | 768 | |||
| Tenofovir/Emtricitabine | 303 (46.5) | 46 (39.3) | <0.001 | |
| Abacavir/Lamivudine | 151 (23.2) | 11 (9.4) | ||
| Tenofovir/Lamivudine | 59 (9.1) | 6 (5.1) | ||
| Zidovudine/Lamivudine | 20 (3.1) | 3 (2.6) | ||
| Other | 104 (16.0) | 11 (9.4) | ||
| Not on cART | 14 (2.2) | 40 (34.2) | ||
| Third drug in cART regimen at interview | 768 | |||
| Nevirapine | 69 (10.6) | 2 (1.7) | <0.001 | |
| Efavirenz | 152 (23.4) | 16 (13.7) | ||
| Lopinavir | 103 (15.8) | 12 (10.3) | ||
| Atazanavir | 249 (38.3) | 42 (35.9) | ||
| Other | 64 (9.8) | 5 (4.3) | ||
| Not on cART | 14 (2.2) | 40 (34.2) |
*
IQR= interquartile range
†
IDU= injecting drug user
**
Not living in a house or apartment
‡
In first year of treatment